Every 10-Q that Genprex Inc (GNPX) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow GNPX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full GNPX filings page.
Genprex, Inc., a clinical-stage gene therapy company, reported a Q2 2026 net loss of $4.45 million, slightly improved from $4.67 million a year earlier, and a six‑month net loss of $8.91 million. The company has no revenue and total operating expenses for the first half were $8.98 million.
Cash and cash equivalents rose to $15.15 million at June 30, 2026 from $7.83 million at year-end 2025, driven mainly by $15.6 million of equity raised under an at‑the‑market facility. Total assets were $17.14 million with modest liabilities of $2.34 million.
Management states there is substantial doubt about the ability to continue as a going concern, even though current cash is expected to fund operations into the second half of 2027, and additional capital will be required. Genprex continues advancing its REQORSA gene therapy in Phase 2 portions of the Acclaim‑1 and Acclaim‑3 lung cancer trials, both with FDA Fast Track Designation and Acclaim‑3 also holding Orphan Drug Designation. The diabetes gene therapy program remains in preclinical development following FDA feedback on IND‑enabling studies. Capital structure was affected by a 1‑for‑50 reverse split in 2025 and a subsequent 1‑for‑22 reverse split in July 2026, with 506,218 shares outstanding at June 30, 2026 and 819,709 shares reported as of August 10, 2026.
Genprex, Inc. reported another quarterly loss as it advances its gene therapy pipeline for lung cancer and diabetes. For the three months ended March 31, 2026, the company generated no revenue and recorded a net loss of $4.46M as operating expenses rose to $4.49M.
Cash and cash equivalents increased to $18.05M, driven mainly by $13.36M of net proceeds from common stock sales under its at-the-market program, raising total stockholders’ equity to $16.93M. Shares outstanding grew sharply to 9,044,856 at March 31, 2026 and 10,586,402 as of May 11, 2026.
The company is enrolling patients in Phase 2 portions of its Acclaim-1 and Acclaim-3 REQORSA lung cancer trials, both benefiting from FDA Fast Track status, with Acclaim-3 also holding Orphan Drug Designation. Its GPX-002 diabetes gene therapy remains in preclinical development under expanded University of Pittsburgh licensing.
Management estimates existing cash will fund operations into the second half of 2027 but acknowledges recurring losses, lack of revenue, and dependence on future financings create substantial doubt about Genprex’s ability to continue as a going concern.
Genprex, Inc. (GNPX) filed its Q3 2025 10‑Q, reporting continued operating losses and active financing to fund clinical programs. The company posted a Q3 net loss of $3,799,240 on operating expenses of $3,345,913, improving from a net loss of $4,315,987 a year ago. For the nine months ended September 30, 2025, net loss was $12,438,742.
Liquidity: Cash and cash equivalents were $1,103,315 as of September 30, 2025. Year‑to‑date, the company used $11,212,938 in operating cash and raised $10,714,593 via equity (including $6,895,947 from the 2023 ATM and $3,818,631 from the 2025 ELOC). Management states current cash is sufficient into March 2026, yet also discloses substantial doubt about continuing as a going concern without further financing.
Capital structure: Shares outstanding were 1,004,247 as of September 30, 2025; a 1‑for‑50 reverse split was completed on October 21, 2025. An ELOC derivative liability of $243,000 was recorded. Pipeline: REQORSA programs Acclaim‑1 (NSCLC) and Acclaim‑3 (ES‑SCLC) are in Phase 2 expansion; both have FDA Fast Track, and Acclaim‑3 also holds Orphan Drug Designation. Interim analyses are planned in 2026.